Tenax Financial Statements From 2010 to 2025

TENX Stock  USD 6.23  0.18  2.81%   
Tenax Therapeutics financial statements provide useful quarterly and yearly information to potential Tenax Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tenax Therapeutics financial statements helps investors assess Tenax Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tenax Therapeutics' valuation are summarized below:
Market Capitalization
25.4 M
Earnings Share
(13.05)
We have found one hundred twenty available fundamental trend indicators for Tenax Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tenax Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Tenax Therapeutics Total Revenue

0.0

Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.64. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tenax Therapeutics Correlation against competitors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Tenax Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.5 M13.4 M24.8 M
Slightly volatile
Short and Long Term Debt Total589.8 K576 K688.1 K
Slightly volatile
Other Current Liabilities790.7 K1.2 M1.3 M
Pretty Stable
Total Current Liabilities4.3 M4.1 M2.7 M
Slightly volatile
Accounts Payable2.5 M2.4 MM
Slightly volatile
Cash9.6 M11.3 M15.7 M
Pretty Stable
Non Current Assets Total1.2 K1.3 K5.3 M
Slightly volatile
Cash And Short Term Investments10 M11.3 M16.4 M
Pretty Stable
Common Stock Shares Outstanding300 K285.7 K114.2 K
Slightly volatile
Liabilities And Stockholders Equity15.5 M13.4 M24.8 M
Slightly volatile
Other Current Assets2.3 M2.2 M659.8 K
Slightly volatile
Other Stockholder Equity368.7 M351.2 M227.2 M
Slightly volatile
Total Liabilities2.8 M4.1 M4.5 M
Slightly volatile
Total Current Assets10.5 M13.4 M17.1 M
Pretty Stable
Short Term Debt604.8 K576 K285.6 K
Slightly volatile
Common Stock25.6527.021 K
Slightly volatile
Common Stock Total Equity1.1 K1.1 K28.3 K
Slightly volatile
Property Plant Equipment172.3 K265.3 K164.1 K
Very volatile
Current Deferred Revenue0.860.9186 K
Slightly volatile
Capital Surpluse226.5 M288.2 M214.5 M
Slightly volatile
Other Liabilities9.6 M9.2 M6.2 M
Slightly volatile
Non Current Liabilities Other46.2 K69.4 K55.9 K
Slightly volatile
Short and Long Term Debt372.4 K576 K306.8 K
Slightly volatile
Net Invested Capital5.1 M7.7 M7.5 M
Slightly volatile
Net Working Capital4.7 M7.3 M6.4 M
Slightly volatile
Capital Stock32.7834.5945
Pretty Stable
Long Term Debt Total99.3 K111.7 K121.8 K
Slightly volatile

Tenax Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.3 K8.7 K114 K
Slightly volatile
Other Operating Expenses8.4 M9.5 M12.1 M
Very volatile
Research Development3.6 M3.7 M5.4 M
Pretty Stable
Total Operating Expenses8.4 M9.5 M12 M
Very volatile
Selling General Administrative4.9 M5.8 M6.7 M
Pretty Stable
Cost Of Revenue8.3 K8.7 K71.9 K
Slightly volatile
Selling And Marketing Expenses6.5 K6.8 K116 K
Slightly volatile
Interest Income1.2 K1.4 K1.5 K
Slightly volatile
Reconciled Depreciation35 K36.9 K41.6 K
Slightly volatile

Tenax Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.3 M2.4 M7.1 M
Very volatile
Depreciation6.5 K6.8 K97.6 K
Slightly volatile
Capital Expenditures2.4 K2.6 K75.3 K
Slightly volatile
Total Cash From Financing Activities8.8 M15.6 M13.8 M
Pretty Stable
End Period Cash Flow7.7 M11.3 M12.4 M
Pretty Stable
Stock Based Compensation16317299.4 K
Slightly volatile
Change To Netincome26.7 M25.4 M11.2 M
Slightly volatile
Issuance Of Capital Stock7.9 M10.6 M8.6 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio141.3 K134.5 K103.5 K
Slightly volatile
Dividend Yield3.313.724.0603
Slightly volatile
Days Sales Outstanding166330294
Slightly volatile
Average Payables375.4 K588.6 K631.6 K
Pretty Stable
Capex To Depreciation0.410.430.5038
Slightly volatile
EV To Sales141.2 K134.5 K103.5 K
Slightly volatile
Inventory Turnover0.540.370.358
Very volatile
Days Of Inventory On HandK1.3 K1.1 K
Very volatile
Cash Per Share33.7635.54K
Very volatile
Income Quality0.530.690.6696
Pretty Stable
Intangibles To Total Assets0.430.410.3996
Slightly volatile
Current Ratio6.173.755.9469
Pretty Stable
Receivables Turnover0.850.92.3566
Slightly volatile
Capex Per Share0.01250.013215.1338
Slightly volatile
Average Receivables27.4 K28.8 K72.4 K
Slightly volatile
Revenue Per Share0.60.6342.3019
Slightly volatile
Interest Debt Per Share2.312.43381
Slightly volatile
Debt To Assets0.04680.04930.1627
Slightly volatile
Operating Cycle400421651
Slightly volatile
Ebt Per Ebit0.820.841.0395
Slightly volatile
Quick Ratio6.113.755.9187
Pretty Stable
Net Income Per E B T1.080.91.0058
Pretty Stable
Cash Ratio5.173.144.9376
Pretty Stable
Days Of Inventory OutstandingK1.3 K1.1 K
Very volatile
Days Of Sales Outstanding166330294
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0257
Slightly volatile
Fixed Asset Turnover0.881.241.6612
Slightly volatile
Debt Ratio0.04680.04930.1627
Slightly volatile
Price Sales Ratio141.3 K134.5 K103.5 K
Slightly volatile
Asset Turnover6.0E-46.0E-40.0439
Slightly volatile
Gross Profit Margin0.530.720.7429
Very volatile

Tenax Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 M2.9 M3.2 M
Slightly volatile
Enterprise Value1.6 M1.8 M1.9 M
Slightly volatile

Tenax Fundamental Market Drivers

Forward Price Earnings0.299
Cash And Short Term Investments9.8 M

Tenax Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Cost Of Revenue8.7 K8.3 K
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 130.94  137.49 
Research And Ddevelopement To Revenue 121.62  127.70 
Capex To Revenue 2.00  2.10 
Revenue Per Share 0.63  0.60 
Ebit Per Revenue(345.72)(328.44)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.